

TABLE 1 Patient characteristics

Characteristic	Total cohort (N = 43)	Refractory (n = 36)	Relapsed (n = 7)
INRG high-risk, n (%)	43 (100)	36 (100)	7 (100)
Sex Male, n (%)	20 (47)	17 (47)	3 (43)
Female, n (%)	23 (53)	19 (53)	4 (57)
Age at diagnosis, years, median (range)	3.3 (1.2–22.7)	3.6 (1.2–10.0)	2.8 (1.9–22.7)
Years from diagnosis, median (range)	0.8 (0.4–3.3)	0.8 (0.4–2.1)	2.7 (0.8–3.3)
Age when treated, years, median (range)	4.8 (1.8–25.7)	4.5 (1.8–10.8)	5.4 (2.8–25.7)
Prior therapies, n (%)			
ICE	41 (95)	35 (97)	6 (86)
TMZ + irinotecan	41 (95)	35 (97)	6 (86)
TOPO + CY	19 (44)	14 (70)	5 (71)
auto-PBSCT	7 (16)	2 (6)	5 (71)
CBT	3 (7)	0	3 (43)
Disease status at the beginning of first IREC therapy, n (%)			
CR	0	0	0
PR	21 (49)	21 (58)	0
SD	11 (26)	8 (22)	3 (43)
PD	11 (26)	7 (19)	4 (57)
<i>UGT1A1</i> gene polymorphism group, n (%)			
Wild type group	20 (47)	17 (47)	3 (42)
Heterozygous group	17 (40)	14 (39)	3 (42)
Homozygous group	6 (14)	5 (14)	1 (14)
<i>UGT1A1</i> genotypes, n (%)			
–/–	20 (47)	17 (47)	3 (43)
–/*6	8 (19)	6 (17)	2 (29)
–/*28	9 (21)	8 (22)	1 (14)
*6/*6	5 (12)	4 (11)	1 (14)
*6/*28	1 (2)	1 (3)	0
*28/*28	0	0	0

Abbreviations: INRG, International Neuroblastoma Risk Group; ICE, ifosfamide, carboplatin, and etoposide; TMZ, temozolomide; TOPO, topotecan; CY, cyclophosphamide; auto-PBSCT, autologous peripheral blood stem cell transplantation; CBT, cord blood stem cell transplantation